Literature DB >> 32476829

New attempt in tuberculosis treatment: autologous cytokine-induced killer after chemotherapy treatment failure in a case of multi-drug resistant tuberculosis (MTB).

Jun-Chi Xu1,2, Xin-Nian Chen2,3, Zhi-Jian Ye2,3, Mei-Ying Wu2,3, Cui-Lin Shi3, Pei-Jun Tang2,3, Hui Chen1,2, Xiao-Yan Zhu1,2, Hua-Feng Song1,2, Xu Ping1,2.   

Abstract

A 32-year-old woman was diagnosed as pulmonary tuberculosis 15 years ago and recurred several times due to long-term nonstandard treatment. Drug sensitivity test indicated that multidrug-resistant tuberculosis had emerged and we determined relevant therapeutic schedule according to this result. However, it didn't show any amelioration of the disease after 3-month chemotherapy. We formulated 3-course CIK immunotherapy based on patient's condition. After 3 courses of immunotherapy, we found obvious amelioration of the patient's condition. And there was no recurrence during the follow-up in the past 3 years. Therefore, we considered that the CIK immunotherapy is an effective method for tuberculosis treatment and recurrence prevention. (Sarcoidosis Vasc Diffuse Lung Dis 2017; 34: 97-99). Copyright:
© 2017.

Entities:  

Keywords:  CIK; cell therapy; multi-drug resistant tuberculosis

Year:  2017        PMID: 32476829      PMCID: PMC7170106          DOI: 10.36141/svdld.v34i1.5084

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  6 in total

1.  Th1 polarization and apoptosis-inducing activity of CD4+ T -cells in cytokine-induced killers might favor the antitumor cytotoxicity of cytokine-induced killers in vivo.

Authors:  Jinpu Yu; Xiubao Ren; Shui Cao; Weihong Zhang; Xishan Hao
Journal:  Cancer Biother Radiopharm       Date:  2006-06       Impact factor: 3.099

Review 2.  Initiation and regulation of T-cell responses in tuberculosis.

Authors:  K B Urdahl; S Shafiani; J D Ernst
Journal:  Mucosal Immunol       Date:  2011-03-30       Impact factor: 7.313

3.  A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.

Authors:  Thomas Leemhuis; Sandra Wells; Christian Scheffold; Matthias Edinger; Robert S Negrin
Journal:  Biol Blood Marrow Transplant       Date:  2005-03       Impact factor: 5.742

4.  Autologous cytokine-induced killer (CIK) immunotherapy in a case of disseminated tuberculosis.

Authors:  Xu Ping; Xu Junchi; Chen Xinnian; Ye Zhijian; Wu Meiying
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2015-06-22       Impact factor: 0.670

5.  Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma.

Authors:  Ming Shi; Bing Zhang; Zi-Rong Tang; Zhou-Yun Lei; Hui-Fen Wang; Yong-Yi Feng; Zhen-Ping Fan; Dong-Ping Xu; Fu-Sheng Wang
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

6.  Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.

Authors:  I G Schmidt-Wolf; R S Negrin; H P Kiem; K G Blume; I L Weissman
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.